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Abstract
Introduction: High daily intensive care unit (ICU) costs are associated with the use of mechanical ventilation (MV) to 
treat acute respiratory failure (ARF), and assessment of quality of life (QOL) after critical illness and cost-effectiveness 
analyses are warranted.
Methods: Nationwide, prospective multicentre observational study in 25 Finnish ICUs. During an eight-week study 
period 958 consecutive adult ICU patients were treated with ventilatory support over 6 hours. Of those 958, 619 (64.6%) 
survived one year, of whom 288 (46.5%) answered the quality of life questionnaire (EQ-5D). We calculated EQ-5D index 
and predicted lifetime quality-adjusted life years (QALYs) gained using the age- and sex-matched life expectancy for 
survivors after one year. For expired patients the exact lifetime was used. We divided all hospital costs for all ARF 
patients by the number of hospital survivors, and by all predicted lifetime QALYs. We also adjusted for those who died 
before one year and for those with missing QOL to be able to estimate the total QALYs.
Results: One-year mortality was 35% (95% CI 32 to 38%). For the 288 respondents median [IQR] EQ-5D index after one 
year was lower than that of the age- and sex-matched general population 0.70 [0.45 to 0.89] vs. 0.84 [0.81 to 0.88]. For 
these 288, the mean (SD) predicted lifetime QALYs was 15.4 (13.3). After adjustment for missing QOL the mean 
predicted lifetime (SD) QALYs was 11.3 (13.0) for all the 958 ARF patients. The mean estimated costs were 20.739 € per 
hospital survivor, and mean predicted lifetime cost-utility for all ARF patients was 1391 € per QALY.
Conclusions: Despite lower health-related QOL compared to reference values, our result suggests that cost per 
hospital survivor and lifetime cost-utility remain reasonable regardless of age, disease severity, and type or duration of 
ventilation support in patients with ARF.
Introduction
Mechanical ventilation (MV) to treat acute respiratory
failure (ARF) is common and it has been suggested that
the use of these methods in ICUs will increase in the
future [1]. Higher daily ICU costs are associated with the
use of MV [2], so the amount of resources spent on this
patient group is an important issue.
Along with a focus shift from short-term to long-term
outcomes, the assessment of health-related quality of life
(HRQOL) has gained more consideration in patients sur-
viving after critical illness [3,4]. A combination of
increased ICU costs and poorer long-term outcomes in
patients with acute respiratory distress syndrome (ARDS)
[5,6], the most severe form of ARF, and in patients need-
ing prolonged MV [7-9], warrant calculations of cost-
effectiveness and cost-utility analysis to be made based
on HRQOL assessment.
Only two studies focusing on quality-adjusted life years
(QALYs) after ARDS are available to date [5,10]. In addi-
tion, one cost-effectiveness study of MV [9] and few stud-
ies concerning subgroups of mechanically ventilated
critical care patients have been published [11-14]. Thus,
prospective large observational studies are needed to
evaluate the outcomes and costs and predict the lifetime
cost-utility of standard critical care in ARF.
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Accordingly, we aimed to analyze one-year mortality
and HRQOL of survivors and to predict lifetime QALYs
gained and costs per QALY in a large prospective cohort,
and relevant subgroups (such as non-invasive ventilation
(NIV)), of consecutive ARF patients admitted to Finnish
ICUs.
Materials and methods
ICUs and study population
We undertook a prospective multicenter cohort study
(FINNALI) in 25 Finnish ICUs. These ICUs cover more
than 97% of the adult population in Finland. During the
eight-week period (between 16 April and 10 June, 2007),
2670 admissions in 25 Finnish ICUs were recorded. The
cohort comprised all adult (≥ 16 years) patients (n = 958)
who received invasive or non-invasive ventilatory sup-
port for more than six hours. NIV in this study comprised
b o t h  c o n t i n u o u s  p o s i t i v e  a i r w a y  p r e s s u r e  ( C P A P )  a n d
non-invasive positive pressure ventilation (NPPV). The
epidemiology of ARF and the basic demographics of the
FINNALI study have been reported previously [15]. This
study is a prospective long-term follow up, QOL and
cost-utility analysis of the FINNALI study.
Data collection
Consent from the ethics committee was granted from
each hospital. The ethics committees waived the need for
informed consent for data registration. For one-year
assessment of HRQOL we asked for a written consent.
An EQ-5D questionnaire was mailed to patients who had
consented. Permission to use the EQ-5D questionnaire
was granted by the EuroQOL Group.
Patient characteristics including age, gender, prior
functional status, admission reason, severity of acute ill-
ness (Simplified Acute Physiology Score (SAPS) II), organ
dysfunction score (Sequential Organ Failure Assessment
(SOFA)), resource use (Therapeutic Intervention Scoring
76 (TISS)) and length of ICU and hospital stay were
obtained from the National ICU quality database (Inten-
sium, Ltd, Kuopio, Finland). Activities of daily life were
coded as: 1) able to work, 2) unable to work, but needs no
help, 3) needs some help and 4) needs help with activities
of daily life. Chronic health state and risk factors 48 hours
before ARF were recorded in the clinical report form. The
clinical report form data were combined with an internet-
based interface to the quality consortium database.
Outcomes
One-year mortality was obtained from Statistics Finland
in 15 May, 2008 [16]. Follow-up time was calculated from
the beginning of ARF.
HRQOL was assessed using the EQ-5D questionnaire, a
standardized HRQOL instrument developed by the Euro-
Qol Group, which has been found to be suitable and rec-
ommended for critically ill patients [3,10,17]. In the
descriptive part of the EQ-5D, the respondents are asked
to describe their health status for five dimensions: mobil-
ity, self-care, usual activities, pain/discomfort, and anxi-
ety/depression. Each dimension is rated on a three-level
scale: no, some, or severe problems. From the resulting
five-digit EQ-5D health profile a weighted EQ index was
calculated using the Finnish reference values [18].
Answers to all five domains were required for EQ-5D
index calculation. For comparing values of respondents to
Finnish population normals [18] the age of the respon-
dent at admission to the ICU was used.
Prediction of lifetime QALYs
We used the same method as the recently published study
of conventional ventilation versus extracorporeal mem-
brane oxygenation (CESAR) [10] for prediction of life
time utility. For patients alive at the one-year follow up,
the age- and gender-adjusted life expectancies from the
year 2007 were obtained from Statistics Finland [16].
First, we predicted lifetime QALYs by multiplying pre-
dicted life expectancy after hospital survival by utility val-
ues (derived from the EQ-5D) for those survivors with
utility values. Second, for patients who died during the
one-year follow up, we used exact life-time after hospital
discharge.
Calculation of costs
Based on previous data [2] we reasoned that the mean
ICU cost is inadequate for MV patients who consume
more resources and individual TISS scores better reflect
resource use. We, therefore, used number of individual
TISS points for each patient during their ICU stay and
the exact number of ward days for cost calculation. The
average cost for one TISS-point (48€ per TISS point) was
calculated by dividing the total annual cost of participat-
ing ICUs by the sum total of the annual TISS points.
Mean ward day price was 416€ in Finnish hospitals [19].
Costs after hospital discharge were not available for eval-
uation. First, all costs (for non-survivors and survivors)
were divided by the number of hospital survivors to cal-
culate cost per hospital survivor. Second, the individual
costs of all one-year survivors were divided by their pre-
dicted total lifetime QALYs to obtain a cost-utility value
for only those with complete quality of life (QOL) data.
Adjustment for missing data and sensitivity analysis
Finally, to confirm the robustness of our estimates we
adjusted, first, for the patients who died before one year
and, second, for those who did not respond to the QOL
questionnaire using the mean QOL of age- and sex-
matched respondents for QALY estimates, as previouslyLinko et al. Critical Care 2010, 14:R60
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published [19]. We assumed that non-survivors had
lower QOL than the whole treated population. Thus, for
those who died we used an estimate of 75% of QOL of the
age- and sex-matched QOL of respondents and used the
exact lifetime during the first year. For the one-year survi-
vors with missing QOL we used the age- and sex-
matched QOL of respondents after comparison to the
QOL respondents. Thus, we calculated an estimate of the
total predicted lifetime QALYs and cost per QALY for the
entire population of 958 ARF patients of the FINNALI
study.
Statistical methods
Data are presented as medians and interquartile ranges
(IQR), absolute values and percentages with 95% confi-
dence intervals (CI) where appropriate, or means (SD).
The two-tailed Mann-Whitney U test was used for com-
parison of continuous variables and the chi-squared test
for categorical variables. Multiple groups were compared
with Kruskal-Wallis test. EQ-5D index and reference val-
ues were analyzed with Wilcoxon's signed matched pair
test. P value less than 0.01 was considered significant in
all tests. SPSS 15.0 (SPSS inc., Chicago, IL, USA) was
used for statistical analyses.
Results
All 958 ARF patients
A total of 958 patients were treated for ARF in ICUs dur-
ing the study period. The flow chart of the study popula-
tion is shown in Figure 1. Comparison of the
characteristics of QOL respondents at one year (n = 288)
and surviving non-respondents are compared in Table 1.
Characteristics of all 958 ARF patients are also included
in Table 1 for comparison. Half of the patients (482 of
949; 50.8%) were able to work before ARF. Only 1.8% (17
of 949) needed help in their daily activities. Daily activity
data were missing for 9 patients.
The one-year mortality rate was 35% (95% CI = 32 to
38%). Duration of MV was not associated with one-year
mortality (P = 0.211). One-year mortality in the group
with the shortest ventilatory support (less than 24 hours)
was 32% (95% CI = 26 to 37%). The mortality (95% CI) in
groups requiring ventilatory support 24 to 96 hours, 96
hours to 21 days, and over 21 days was 35% (30 to 40%),
40% (34 to 45%), and 31% (14 to 48%), respectively. How-
ever, a significant difference was found between the dif-
ferent ventilatory support groups. One-year mortality
(95% CI) was lowest, 33% (95% CI = 30 to 36%), in
patients treated with only invasive ventilation. In patients
with NIV only, NIV failure during first six hours and NIV
failure after six hours of treatment start were 37% (28 to
47%), 60% (45 to 76%) and 49% (31 to 66%), respectively
(P = 0.001; 45% in all with NIV). One-year mortality in
acute lung injury/ARDS patients was 51% (39 to 64%).
The 288 one-year survivors with complete QOL data
Of the 292 returned EQ-5D questionnaires, 202 (69%)
were given by patients, 42 (14%) by next of kin, and in 44
(15%) the respondent was unknown. The EQ-5D index
could be calculated for 288 patients after one year (47% of
619 one-year survivors, and 67% of patients with con-
sent). The only differences between the respondents and
non-respondents were that the non-respondents were
younger and more often patients with emergency admis-
sions (Table 1).
The degree of impairment in each EQ-5D dimension is
presented in Table 2. The EQ-5D index at one-year was
lower than the age-matched and sex-matched reference
value (0.70 (0.45 to 0.89) vs. 0.84 (0.81 to 0.88), P < 0.001).
The EQ-5D index of the normal population declines with
age, so one-year indexes are presented according to dif-
ferent age groups in Figure 2, separately for short postop-
erative patients (Figure 2a) and all other patients (Figure
2b). No significant difference in EQ-5D indices among
one-year survivors was found between the age groups (P
= 0.068 for men, P = 0.265 for women). However, signifi-
cant differences were detected in all but the two oldest
age groups when compared with the reference popula-
tion. These 288 patients gained 6,583 life-years and 4,434
predicted lifetime QALYs (2,286 life-years and 1,540
QALYs per 100 one-year survivors). For these 288 one-
year survivors the mean (SD) predicted life-years and life-
time QALYs were 22.9 (14.4) and 15.4 (13.3), respectively.
The estimated total costs for these 288 were 4,830,402€
and 1,089€ per one predicted lifetime QALY.
Adjusted QOL and QALY for whole population
After adjustment for missing QOL assessments the
median (IQR) sum index of EQ-5D for the total popula-
tion was 0.60 (0.49 to 0.72). Accordingly, our 958 ARF
patients were estimated to gain a total of 16,076 life years
and 10,857 predicted lifetime QALYs (67 life-years and 44
QALYs in one year per 100 patients).
Overall the calculated costs (of survivors and non-sur-
vivors) for ICU and hospital stay were 20,739€ per hospi-
tal survivor. The proportion of ICU costs with regard to
the total hospital cost (ICU and ward costs) were 73%,
69% and 87% for all, survivors and non-survivors, respec-
tively (P  < 0.001). For all 958 ARF patients (including
non-survivors) the mean (SD) predicted life-years was
16.8 (17.2) and lifetime QALYs were 11.3 (13.0), respec-
tively. Our calculation yielded a mean cost per lifetime
QALY of 1,391€/QALY with a seven-fold range from
670€ to 5,263€ according to different age groups, pread-
mission status, admission type and disease severity (Table
3). When patients with short ventilation support (< 1day)
after surgical procedure were excluded the mean cost per
lifetime QALY for the rest of the patients was 1,483€/
QALY. Estimated mean costs, predicted lifetime QALYLinko et al. Critical Care 2010, 14:R60
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and costs per QALY in different age groups of all ARF
patients are presented in Figure 3. Both the cost per hos-
pital survivor and the cost per lifetime QALY increased
with the number of chronic illnesses and risk factors for
ARF. Patients with unsuccessful NIV had the highest
costs (42,625 to 44,971€ per hospital survivor). Individual
costs and outcomes indicate that for 85% of our ARF hos-
pital survivors the costs were lower than 20,000€ and for
88% they were lower than 50,000€ per predicted lifetime
QALY. Among the patients with costs exceeding 20,000€,
27% (63 of 235) died before hospital discharge.
Discussion
This prospective multicenter observational study of criti-
cally ill patients with ARF in 25 Finnish ICUs found that
the 288 one-year survivors with complete QOL data were
predicted to gain a mean of 22.9 life-years and 15.4 life-
time QALYs with a cost-utility of 1,089€ per lifetime
QALY. After adjustment for missing values, the 958 ARF
patients were estimated to gain a mean of 16.8 life-years
and a mean of 11.3 predicted lifetime QALYs with a cost-
utility of 1,391€ per one predicted lifetime QALY.
We used the EQ-5D as a measurement of HRQOL
because it has been reported as suitable for critically ill
patients [3], it may be answered reliably by the next of kin
[20,21], and it has been previously used for cost-utility
analysis in the critically ill [19,22,23]. More recently, a
cost-utility evaluation alongside a large randomized trial
comprising ARF and treatment with extracorporeal
membrane oxygenation also used EQ-5D questionnaires
(six months after critical illness) with UK tariff values for
utility [10]. In concordance with our study, that study
assumed a utility of 0 at the time of onset of treatment.
This approach differs from cost-utility calculations for
other medical treatment where a control group with no
treatment is included. This kind of study design in ARF
patients without MV would be unfeasible and unethical.
Thus, an ordinary cost-utility analysis based on QOL
comparison before and after treatment is not suitable in
this specific setting of life-threatening illness where with-
drawing MV means death. In the critical care setting, the
ordinary concept of a control group seems to be only
valid with regard to treatments, which are added on top
of the vital life support such as MV, as in the CESAR
study [10]. Accordingly, we did not include any compari-
sons to pre-ICU QOL but evaluated only QOL after criti-
cal illness for utility.
Table 1: Demographic data of study patients. Data are presented as numbers (percentages) or median (interquartile 
range). Statistical significance was tested between respondents (n = 288) and non-respondents of quality of life 
questionnaire (EQ-5D) at one year
ARF patients
(n = 958)
One-year survivors (n = 619)
Respondents 
(n = 288)
Non-respondents 
(n = 331)
P value
Age, years 63 (51-74) 64 (53-74) 55 (41-66) < 0.001
Gender, male n (%) 637 (66.5%) 195 (67.7%) 220 (66.5%) 0.74
SAPS II, points 43 (31-55) 37 (27-49) 37 (27-48) 0.99
SOFA, points 8 (6-10) 7 (5-9) 7 (5-9) 0.81
TISS, points, average 34 (29-41) 34 (29-43) 33 (28-39) 0.04
TISS, points, total 151 (90-280) 146 (95-271) 145 (78-264) 0.18
Operative n (%) 375 (39.1%) 143 (49.7%) 136 (41.1%) 0.03
Emergency n (%) 821 (85.7%) 217 (75.3%) 289 (87.3%) < 0.001
Ventilatory support, 
days
2 (1-5) 2 (1-4) 2 (1-5) 0.81
ICU length of stay, days 3 (2-7) 3 (2-7) 3 (2-7) 0.29
Hospital length of stay, 
days
11 (6-21) 13 (8-23) 12 (7-23) 0.19
ALI/ARDS n (%) 68 (7.0%) 13 (4.5%) 20 (6.0%) 0.40
ALI, acute lung injury; ARDS, adult respiratory distress syndrome; ARF, acute respiratory failure; SAPS II, Simplified Acute Physiology Score; 
SOFA, Sequential Organ Failure Assessment; TISS, Therapeutic Intervention Scoring 76.Linko et al. Critical Care 2010, 14:R60
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In agreement with previous studies [24-28] we detected
lower QOL after ARF compared with the age-matched
and sex-matched reference values. HRQOL decreases
after ARF [29] and ARDS [5], and it may even be lower
after ARDS compared with other critically ill patients
[30]. Of note, the QOL after ARF may be largely influ-
enced by severity of dysfunction and mortality rate.
The one-year mortality in this national cohort of ARF
patients was 35%, which is below the previously reported
range (range for one-year survival 44 to 65%) [5,7,29,31].
However, different definitions limit definite conclusions.
The inclusion criteria for this study were a need for venti-
latory support exceeding six hours using either invasive
Figure 1 Flow-chart of study population for quality of life and 
cost-utility evaluation. ARF, acute respiratory failure; QALY, quality-
adjusted life years.
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Table 2: Distribution of responses to EQ-5D modalities at one year. Data are presented as number (percentage)
Problems n = 288
Mobility
No 120 (42%)
Some 128 (44%)
Severe 40 (14%)
Self-care
No 188 (65%)
Some 75 (26%)
Severe 25 (9%)
Usual activities
No 125 (45%)
Some 113 (39%)
Severe 50 (17%)
Pain/discomfort
No 86 (30%)
Some 170 (59%)
Severe 29 (11%)
Anxiety/depression
No 153 (53%)
Some 121 (42%)
Severe 14 (5%)
Figure 2 EQ-5D index of respondents of acute respiratory failure 
at one year compared with reference values. Patients are divided to 
(a) post-operative patients with short (< 1 day) ventilatory support and 
(b) other patients. P = 0.005 in age group 65 to 74 years.Linko et al. Critical Care 2010, 14:R60
http://ccforum.com/content/14/2/R60
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Table 3: Predicted cost-utilities in subgroups of patients with acute respiratory failure
n Gained survival 
(years)
QALYs (years) Cost/hospital 
survivor
Cost/QALY
mean (SD) mean (SD) €€
Age (years)
≤ 51 252 36 (19) 25 (16) 19,195 670
52-63 236 17 (11) 11 (8) 21,069 1,582
64-74 251 9 (8) 6 (6) 21,499 2,620
≥ 75 219 4 (5) 3 (3) 21,737 5,263
SAPS II (points)
≤ 31 253 28 (18) 20 (15) 15,187 726
32-43 246 18 (16) 11 (12) 22,545 1,656
44-55 222 13 (15) 8 (11) 23,565 2,026
≥ 56 237 8 (13) 5 (9) 24,760 2,560
Activities of daily life
Able to work 482 23 (19) 16 (14) 19,718 1,028
Unable to work but needs no 
help
337 12 (13) 8 (9) 21,665 2,075
Needs some help 113 8 (12) 5 (9) 21,512 2,722
Needs help to activities of daily 
life
17 8 (15) 5 (12) 30,653 3,450
Admission type
Elective 133 16 (14) 12 (12) 17,273 1,283
Emergency 821 17 (18) 11 (13) 21,462 1,410
Ventilatory support
NIV only 105 15 (17) 11 (14) 13,154 956
Invasive ventilation only 775 17 (17) 12 (13) 20,065 1,313
NIV and invasive ventilation 
before 6 hours
43 11 (16) 6 (9) 42,625 3,733
NIV and invasive ventilation 
after 6 hours
35 13 (17) 8 (11) 44,971 3,499
Chronic diseases, count
0 425 23 (19) 16 (15) 19,065 966
1 320 13 (15) 8 (11) 22,583 1,936
2 158 10 (11) 7 (9) 21,699 2,337
3 47 9 (9) 6 (6) 24,400 3,102
4 8 8 (9) 4 (5) 34,108 3,910
ARF risk factors 48 hours before
Sepsis 136 14 (15) 9 (12) 37,219 2,599
Cardiac insufficiency 192 9 (12) 6 (8) 27,322 2,779
Pneumonia 114 14 (16) 9 (12) 26,368 2,106
Post-operative with ventilatory 
support < 1 day
132 17 (15) 12 (12) 11,025 836
Chronic diseases include chronic obstructive pulmonary disease, chronic restrictive pulmonary disease, chronic heart disease, diabetes mellitus, 
immunodeficiency, neuromuscular disease.
ARF, acute respiratory failure; NIV, non-invasive ventilation; SAPS II, Simplified Acute Physiology Score; SD, standard deviation; QALY, quality-
adjusted life year.Linko et al. Critical Care 2010, 14:R60
http://ccforum.com/content/14/2/R60
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or non-invasive methods. Surprisingly, survival in the
group that received the longest ventilatory support, over
21 days was as low as 31%, lower than the 51% and 58% in
previous reports of prolonged MV [9,32]. Differences in
decisions to withhold or withdraw treatments after a
period of treatment effort may be one plausible explana-
tion for this. In addition, the one-year mortality rate for
those with NIV was 45% compared with 33% for those
with invasive ventilation. Thus, studies in ARF patients
including only patients with a special type or specified
duration of MV may report varying survival rates. Thus,
the varying inclusion criteria of different studies affect
the predicted lifetime cost-utility.
Health care technologies that cost less than $20,000 per
QALY are widely accepted, but even cut-off values as high
as $100,000 per QALY have been considered [33]. The
National Institute of Clinical Excellence (NICE) would be
unlikely to reject any technology with a ratio in the range
of £5,000 to £15,000 per QALY solely on the ground of
cost-ineffectiveness [34]. Our sensitivity analysis (Table
3) showed that the cost remained below the lower cut-off
value of NICE in all subsets. Thus, we consider our treat-
ment cost-effective. Furthermore, compared with the
Gross Domestic Product per capita (in Finland $37,200
2007 [35]) the cost-utility (as €/QALY) was lower in all
subgroups of ARF patients. We detected remarkable dif-
ferences in cost per QALY with increasing age and dis-
ease severity. Our finding is in parallel with the study by
Hamel and colleagues in patients with pneumonia and
ARDS [14]. However, in their study the cost range was
considerably higher, from $19,000 to $200,000 per QALY
according to different risk estimates and sensitivity analy-
sis. Even without costs after discharge from hospital, hos-
p i t a l  c o s t  w a s  h i g h e r  t h a n  i n  o u r  s t u d y .  E v e n  h i g h e r
hospital costs ($165,075 to $423,596) have been reported
for prolonged MV [9]. In addition, diagnostic category
also influences cost among the critically ill [20,36,37].
Pneumonia and ARDS have been among the most expen-
sive diagnosis groups in previous studies [14,35,38] and in
a recent review [39]. In the absence of a gold standard for
cost-effectiveness analysis, different ways to calculate
costs and report the analysis make direct cost compari-
sons challenging [40].
To the best of our knowledge, this is the largest cost-
utility analysis based on a nationwide prospective multi-
center cohort of consecutive ARF patients. For QOL
assessment we used EQ-5D, which is frequently used for
QALY assessment in health care [41] and, despite its limi-
tations, recommended for evaluations in the critical care
setting [3], and reported recently in this setting with sim-
ilar approach [10].
Our study has some limitations. First, we used an esti-
mation of life expectancy for survivors to enable cost-util-
ity over a lifetime horizon to be calculated, as previously
published [10,19]. This approach includes an assumption
that the life-time for survivors of ARF will be comparable
with that of an age-matched and sex-matched population.
We used one-year follow up instead of six months, as in
the CESAR trial [10]. The survival after critical illness has
been shown to be comparable with the Finnish popula-
tion based reference values after two years [42]. However,
we consider our follow up to be sufficiently long because
mortality in our ARF patients was stable after six months,
in keeping with previous reports [5,6,43]. Second, QOL
was evaluated after one year and may not, even then, reli-
ably reflect the QOL for the remainder of life. On the
other hand, one-year follow up is generally accepted to be
adequate [4,44]. Third, multiplying the life-time estimate
by QOL at one-year follow up without adjusting for time
differences does not take into account the gradual decline
of QOL with age. However, we did not find any signifi-
cant differences between the respondents of different age
groups. In reference EQ-5D sum index values, the decline
from the youngest to the oldest is 15 to 20% in the Finnish
reference population. This decline would, therefore, cor-
respond to a less than 10% increase in the estimated cost
per QALY.
Fourth, all costs per QALY estimates are sensitive to
differences in patient demographics and outcome. We,
therefore, calculated costs separately for those with QOL
assessment and also adjusted for patients with missing
data. If we had only included one-year survivors, as some
other studies with different critically ill patients [45], with
QOL data available, that would have caused a significant
bias because the surviving patients are not representative
for the whole ICU population. We, therefore, also
adjusted for missing patients with an approach similar to
other studies [10,19,46] and performed a sensitivity anal-
ysis for different subgroups of patients ending up with
acceptable estimates of up to 5,263€ per QALY for all
these subgroups. Fifth, of note, these estimates do not
Figure 3 Estimated mean costs and predicted lifetime quality-ad-
justed life years (QALY) and costs per QALY in different age 
groups.
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include post-discharge costs or annual health service use
as in some other studies [7,14]. Thus, our estimates only
include hospital costs for the ARF treatment and under-
estimate the total costs of care during the first year.
Finally, precise costs of the care are difficult to gather
and to compare with other studies because different cal-
culations are used for ICU and hospital charges. We did
not register the costs for each patient using a bottom-up
method [40,47]. In order to be comparable with the latest
F i n n i s h  s t u d y  i n  s e v e r e  s e p s i s  [ 1 9 ]  w e  u s e d  t h e  s a m e
methodology for ICU and hospital costs adjusting for the
use of ICU resources using individual TISS points for
each patient in our calculations as previously published
[48].
Conclusions
W e conclude that two-thirds of our ARF patients were
alive at one-year follow up. Despite lower HRQOL com-
pared with population reference value, our results suggest
that the cost per one predicted lifetime QALY remains
reasonable in these patients with ARF regardless of age,
disease severity, or type and duration of MV.
Key messages
• One-year mortality in ARF patients was 35% (95%
CI = 32 to 38%).
• EQ-5D index after one year was lower than that of
an age-matched and sex-matched general population.
• Cost per hospital survivor and life-time cost-utility
remain reasonable regardless of age, disease severity,
and type or duration of ventilatory support in patients
with ARF.
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